Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A massive study of 134,548 Mexicans reveals that Indigenous American genomic ancestry is a potent, independent risk factor for type 2 diabetes and prediabetes, highlighting an urgent need for population-specific preventive healthcare strate
A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em
A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.
This study reveals that combining stress hyperglycemia ratio and glucose variability significantly improves mortality prediction in sepsis, with risk patterns varying significantly based on a patient’s baseline metabolic status (Norma
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in me
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1
This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic
A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends h
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra
A secondary analysis of the EMERGE trial reveals that Random Survival Forest models utilizing early glycemic data can accurately predict the time to insulin initiation in women with gestational diabetes, offering a roadmap for personalized
A 6-month randomized controlled trial reveals that varying dietary sweet taste exposure does not alter sweet taste liking, energy intake, or body weight, questioning the efficacy of public health recommendations to reduce sweet exposure for
A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing swee
A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible
This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate
Open language-specific specialty feeds and department pages.